NYSE: CRCrane Co Stock
$167.55-7.03 (-4.03%)
Updated Mar 26, 2026
CR Price
$167.55
Fair Value Price
N/A
Market Cap
$9.66B
52 Week Low
$127.04
52 Week High
$214.31
P/E
26.26x
P/B
4.69x
P/S
4.6x
PEG
2.25x
Dividend Yield
0.56%
Revenue
$2.31B
Earnings
$366.60M
Gross Margin
42.2%
Operating Margin
20.78%
Profit Margin
15.9%
Debt to Equity
0.87
Operating Cash Flow
$395M
Beta
1.27
Next Earnings
May 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CR's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Specialty Industrial Machinery
Industry Rating
A
CR
Ranked#9 of 68
Ranked#9 of 68
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $75.01 | A | |
| $65.69 | A | |
| $22.71 | A |
Be the first to know about important CR news, forecast changes, insider trades & much more!
CR News
Overview
Due Diligence Score
–
Industry Average (35)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CR scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CR ($167.55) is trading above its intrinsic value of $60.76, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CR is good value based on its earnings relative to its share price (26.26x), compared to the US market average (31.07x)
P/E vs Market Valuation
CR is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more CR due diligence checks available for Premium users.
Valuation
CR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
26.26x
Industry
22.17x
Market
31.07x
CR is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CR is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.69x
Industry
5.2x
CR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CR price to earnings growth (PEG)
For valuing profitable companies with growth potential
CR is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
CR's financial health
Profit margin
Revenue
$581.0M
Net Income
$81.7M
Profit Margin
14.1%
CR's Earnings (EBIT) of $479.00M... subscribe to Premium to read more.
Interest Coverage Financials
CR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.9B
Liabilities
$1.8B
Debt to equity
0.87
CR's short-term assets ($2.57B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CR's short-term assets ($2.57B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$205.8M
Investing
-$4.7M
Financing
$1.1B
CR's operating cash flow ($394.80M)... subscribe to Premium to read more.
Debt Coverage Financials
CR vs Specialty Industrial Machinery Stocks
Crane Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.